Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication

INTERVENTION:

Prostaglandin for injection (alprostadil) group: 60 mcg of prostaglandin for injection is intravenously administered once a week or more. This therapy is repeated 10 times or more. Ripple injection (alprostadil Injection) group: 10 mcg of ripple injection is administered intravenously once a week or more. This treatment is repeated 10 times or more. Conventional treatment group

CONDITION:

Patients with combined lumbar spinal stenosis and arteriosclerosis obliterans

PRIMARY OUTCOME:

The Japanese Orthopaedic Association (JOA) score

SECONDARY OUTCOME:

Age, sex, affected period, biochemical examination of blood, details of treatment (number and frequency of infusions, concomitant drug therapy, block therapy, and other conservative therapies), SF‐36

, VAS INCLUSION CRITERIA:

The subjects are patients who meet all of the following inclusion criteria and are able to provide informed consent. 1) Male and female patients aged 20 years or older. 2) Patients who are diagnosed with lumbar spinal stenosis based on X‐ray and MRI findings and are undergoing conservative treatment. 3) Patients who are diagnosed with arteriosclerosis obliterans (peripheral arterial disease) Fontaine classification I or II. 4) Patients who understand the objectives of this study and provide informed consent.